Page last updated: 2024-09-04

diaminoguanidine and Diabetes Mellitus, Type 2

diaminoguanidine has been researched along with Diabetes Mellitus, Type 2 in 1 studies

*Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. [MeSH]

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Chen, L; Chen, Z; Ge, X; He, X; Huang, Y; Jiang, X; Lin, Z; Liu, B; Liu, T; Xu, W; Zeng, F; Zhao, C; Zhao, L; Zhu, Y1

Other Studies

1 other study(ies) available for diaminoguanidine and Diabetes Mellitus, Type 2

ArticleYear
6,8-(1,3-Diaminoguanidine) luteolin and its Cr complex show hypoglycemic activities and alter intestinal microbiota composition in type 2 diabetes mice.
    Food & function, 2022, Mar-21, Volume: 13, Issue:6

    Topics: Animals; Chromium; Diabetes Mellitus, Type 2; Gastrointestinal Microbiome; Glycogen Synthase Kinase 3 beta; Guanidines; Hypoglycemic Agents; Luteolin; Mice; Organometallic Compounds; Phosphatidylinositol 3-Kinases

2022